# US 2023/0053787 A1 · Methods related to toxicity and response associated with cell therapy for treating b cell malignancies

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0053787 A1
- Document ID: US20230053787A1
- Status: Published application
- Kind: A1
- Application number: 17/782,584
- Filed: 2020-12-04
- Published: 2023-02-23
- Earliest claimed: 2019-12-06
- Assignees: Juno Therapeutics, Inc.
- Applicants: Juno Therapeutics, Inc.
- Inventors: Jason A. DUBOVSKY; Julie RYTLEWSKI; Ethan THOMPSON; Jerill THORPE
- Web page: https://patentgrep.com/patent/US20230053787A1

## CPC

- G01N 33/5014: {for testing toxicity}
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/31: Chimeric antigen receptors [CAR]
- A61K 40/414: {Nervous system antigens}
- A61K 40/4211: {CD19 or B4}
- C07K 14/7051: {T-cell receptor (TcR)-CD3 complex}
- G01N 33/57505: of the blood, e.g. leukaemia
- G01N 33/6863: {Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors}
- A61K 2039/804: {Blood cells [leukemia, lymphoma]}
- C07K 2319/03: containing a transmembrane segment
- C12N 5/0636: {T lymphocytes}
- G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- G01N 2800/56: Staging of a disease; Further complications associated with the disease
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Provided are methods for determining the risk of toxicity (e.g., neurotoxicity) and/or the likelihood of response to a cell therapy. In some aspects, the methods generally involve assessing parameters or biomarkers (e.g., blood analytes) that are associated with toxicity and/or response. In some aspects, the methods relate to adoptive cell therapy involving the administration of doses of cells for treating subjects with certain B cell malignancies, such as chronic lymphocytic leukemia (CLL), such as relapsed or refractory CLL, or small lymphocytic lymphoma (SLL). The cells for the adoptive cell therapy generally express recombinant receptors such as chimeric antigen receptors (CARs). In some aspects, the methods can be used to identify or select subjects for treatment, for example, with a cell therapy.

## Claims

### Claim 1

A method of determining the risk of developing a toxicity after administration of a cell therapy, the method comprising:
assessing one or more parameters of disease burden selected from among lymph node tumor burden, blood tumor burden and the ratio of blood tumor burden to lymph node tumor burden, in a subject having a chronic lymphoblastic leukemia (CLL) or a small lymphocytic lymphoma (SLL) that is a candidate for treatment with a cell therapy, said cell therapy comprising a dose of engineered cells comprising T cells expressing a chimeric antigen receptor (CAR) that binds cluster of differentiation 19 (CD19), wherein the parameter is assessed from the subject prior to administering the cell therapy; and
comparing, individually, the value of the one or more parameters to a threshold level for the respective parameter, wherein:
(1) identifying the subject as at risk for developing a neurotoxicity following administration of the cell therapy if: (a) the lymph node tumor burden is at or above the threshold level for lymph node tumor burden; (b) the blood tumor burden is below the threshold level for blood tumor burden; and/or (c) the ratio of blood tumor burden to lymph node tumor burden is below the threshold level for the ratio; or
(2) identifying the subject as not at risk for developing a neurotoxicity following administration of the cell therapy if: (a) the lymph node tumor burden is below the threshold level for tumor burden; (b) the blood tumor burden is at or above the threshold level for blood tumor burden; and/or (c) the ratio of blood tumor burden to lymph node tumor burden is above the threshold level for the ratio.

### Claim 2 (depends on 1)

The method of claim 1, wherein if the subject is identified as at risk for developing a neurotoxicity, the method further comprises:
(i) administering to the subject the cell therapy, optionally at a reduced dose, optionally wherein:
(a) the method further comprises administering to the subject an agent or other treatment capable of treating, preventing, delaying, reducing or attenuating the development or risk of development of the neurotoxicity; and/or
(b) the administering of the cell therapy to the subject is carried out or is specified to be carried out in an in-patient setting and/or with admission to a hospital for one or more days; or
(ii) administering to the subject an alternative treatment other than the cell therapy for treating the CLL or SLL.

### Claim 3 (depends on 1)

The method of claim 1, wherein if the subject is identified as not at risk for developing a neurotoxicity, the method further comprises:
(i) administering to the subject the cell therapy, optionally wherein:
(a) the subject is not administered an agent or other treatment capable of treating, preventing, delaying, reducing or attenuating the development or risk of development of a toxicity unless or until the subjects exhibits a sign or symptom of a toxicity, optionally at or after the subject exhibits a sustained fever or a fever that is or has not been reduced or not reduced by more than 1° C. after treatment with an antipyretic; and/or
(b) the administering of the cell therapy and any follow-up is carried out on an outpatient basis and/or without admitting the subject to a hospital and/or without an overnight stay at a hospital and/or without requiring admission to or an overnight stay at a hospital, optionally unless or until the subject exhibits a sustained fever or a fever that is or has not been reduced or not reduced by more than 1° C. after treatment with an antipyretic.

### Claim 4

A method of selecting a subject for treatment with a cell therapy, wherein the method comprises:
assessing one or more parameters of disease burden selected from among lymph node tumor burden, blood tumor burden and the ratio of blood tumor burden to lymph node tumor burden, in a subject having a chronic lymphoblastic leukemia (CLL) or a small lymphocytic lymphoma (SLL) that is a candidate for treatment with a cell therapy, said cell therapy comprising a dose of engineered cells comprising T cells expressing a chimeric antigen receptor (CAR) that binds cluster of differentiation 19 (CD19), wherein the parameter is assessed from the subject prior to administering the cell therapy; and
comparing, individually, the value of the one or more parameters to a threshold level for the respective parameter, wherein:
(1) if (a) the lymph node tumor burden is at or above the threshold level for lymph node tumor burden; (b) the blood tumor burden is below the threshold level for blood tumor burden; and/or (c) the ratio of blood tumor burden to lymph node tumor burden is below the threshold level for the ratio, selecting the subject for:
(i) administration of the cell therapy at a reduced dose;
(ii) administration of an agent or other treatment capable of treating, preventing, delaying, reducing or attenuating the development or risk of development of the neurotoxicity;
(iii) administration of the cell therapy that is carried out or is specified to be carried out in an in-patient setting and/or with admission to a hospital for one or more days; and/or
(iv) administration of an alternative treatment other than the cell therapy for treating the CLL or SLL; or
(2) if (a) the lymph node tumor burden is below the threshold level for tumor burden; (b) the blood tumor burden is at or above the threshold level for blood tumor burden; and/or (c) the ratio of blood tumor burden to lymph node tumor burden is above the threshold level for the ratio, selecting the subject for:
(i) administration of the cell therapy, optionally wherein:
(a) the subject is not administered an agent or other treatment capable of treating, preventing, delaying, reducing or attenuating the development or risk of development of a toxicity unless or until the subjects exhibits a sign or symptom of a toxicity, optionally at or after the subject exhibits a sustained fever or a fever that is or has not been reduced or not reduced by more than 1° C. after treatment with an antipyretic; and/or
(b) the administration of the cell therapy and any follow-up is carried out on an outpatient basis and/or without admitting the subject to a hospital and/or without an overnight stay at a hospital and/or without requiring admission to or an overnight stay at a hospital, optionally unless or until the subject exhibits a sustained fever or a fever that is or has not been reduced or not reduced by more than 1° C. after treatment with an antipyretic.

### Claim 5 (depends on 4)

The method of claim 4, further comprising administering the cell therapy, the agent or other treatment capable of treating, preventing, delaying, reducing or attenuating the development or risk of development of a toxicity and/or the alternative treatment to the subject.

### Claim 6 (depends on 1, 2, 3, 4, 5)

The method of any of claims 1-5, wherein the assessing the blood tumor burden comprises determining the lymphocyte concentration in the blood of the subject.

### Claim 7 (depends on 6)

The method of claim 6 wherein the concentration is the lymphocyte count per microliter (μL) of blood.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6, 7)

The method of any of claims 1-7, wherein the threshold level for blood tumor burden is a value between at or about 800 lymphocytes/μL and at or about 3000 lymphocytes/μL.

### Claim 9 (depends on 8)

The method of claim 8, wherein the threshold level for blood tumor burden is a value of at or about 800 lymphocytes/μL, 900 lymphocytes/μL, 1000 lymphocytes/μL, 1250 lymphocytes/μL, 1500 lymphocytes/μL, 1750 lymphocytes/μL, 2000 lymphocytes/μL, 2250 lymphocytes/μL, 2500 lymphocytes/μL, 2750 lymphocytes/μL or 3000 lymphocytes/μL, or a value between any of the foregoing.

### Claim 10 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

The method of any of claims 1-9, wherein the assessing the lymph node tumor burden comprises determining the largest lymph node diameter.

### Claim 11 (depends on 10)

The method of claim 10, wherein the largest lymph node diameter is measured in centimeters (cm).

### Claim 12 (depends on 10, 11)

The method of claim 10 or claim 11, wherein the threshold level for the largest lymph node diameter as the lymph node tumor burden is a value between at or about 4 cm and at or about 7 cm.

### Claim 13 (depends on 10, 11, 12)

The method of any of claims 10-12, wherein the threshold level for the largest lymph node diameter as the lymph node tumor burden is a value of at or about 4 cm, 4.25 cm, 4.5 cm, 4.75 cm, 5 cm, 5.25 cm, 5.5 cm, 5.75 cm, 6 cm, 6.25 cm, 6.5 cm, 6.75 cm or 7 cm, or a value between any of the foregoing.

### Claim 14 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

The method of any of claims 1-9, wherein the assessing the ratio of blood tumor burden to lymph node tumor burden comprises determining the ratio of the lymphocyte count per microliter (μL) of blood to the largest lymph node diameter in centimeters (cm).

### Claim 15 (depends on 14)

The method of claim 14, wherein the threshold level for ratio of the lymphocyte count per microliter (μL) of blood to the largest lymph node diameter in centimeters (cm) as the ratio of blood tumor burden to lymph node tumor burden is a value between at or about 300 and at or about 1000.

### Claim 16 (depends on 14, 15)

The method of claim 14 or claim 15, wherein the threshold level for ratio of the lymphocyte count per microliter (μL) of blood to the largest lymph node diameter in centimeters (cm) as the ratio of blood tumor burden to lymph node tumor burden is a value of at or about 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950 or 1000, or a value between any of the foregoing.

### Claim 17 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

The method of any of claims 1-9, wherein the assessing the lymph node tumor burden comprises determining the sum of the products of diameters (SPD).

### Claim 18 (depends on 17)

The method of claim 17, wherein the SPD is measured in centimeters squared (cm2).

### Claim 19 (depends on 17, 18)

The method of claim 17 or claim 18, wherein the threshold level for the SPD as the lymph node tumor burden is a value between at or about 10 cm2 and at or about 40 cm2.

### Claim 20 (depends on 17, 18, 19)

The method of any of claims 17-19, wherein the threshold level for the SPD as the lymph node tumor burden is a value of at or about 10 cm2, 12.5 cm2, 15 cm2, 17.5 cm2, 20 cm2, 22.5 cm2, 25 cm2, 27.5 cm2, 30 cm2, 32.5 cm2, 35 cm2, 37.5 cm2 or 40 cm2, or a value between any of the foregoing.

### Claim 21 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 17, 18, 19, 20)

The method of any of claims 1-9 and 17-20, wherein the assessing the ratio of blood tumor burden to lymph node tumor burden comprises determining the ratio of the lymphocyte count per microliter (μL) of blood to the sum of the products of diameters (SPD) in centimeters squared (cm2).

### Claim 22 (depends on 21)

The method of claim 21, wherein the threshold level for ratio of the lymphocyte count per microliter (μL) of blood to SPD as the ratio of blood tumor burden to lymph node tumor burden is a value between at or about 25 and at or about 500.

### Claim 23 (depends on 21, 22)

The method of claim 21 or claim 22, wherein the threshold level for ratio of the lymphocyte count per microliter (μL) of blood to SPD as the ratio of blood tumor burden to lymph node tumor burden is a value of at or about 25, 50, 75, 100, 150, 200, 250, 300, 350, 400, 450 or 500, or a value between any of the foregoing.

### Claim 24 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23)

The method of any of claims 1-23, wherein value of the one or more parameters of disease burden is the value of the one or more parameters of disease burden prior to administration of a lymphodepleting therapy to the subject.

### Claim 25

A method of determining the risk of developing a toxicity after administration of a cell therapy, the method comprising:
assaying a biological sample for the level, amount or concentration of tumor necrosis factor (TNF) and/or interleukin-16 (IL-16), wherein the biological sample is from a subject having a chronic lymphoblastic leukemia (CLL) or a small lymphocytic lymphoma (SLL) that is a candidate for treatment with a cell therapy, said cell therapy comprising a dose of engineered cells comprising T cells expressing a chimeric antigen receptor (CAR) that binds cluster of differentiation 19 (CD19), wherein the biological sample is obtained from the subject prior to administering the cell therapy or prior to peak CAR+ T cell expansion and/or within at or about 11 days after the initiation of administration of the cell therapy; and
comparing, individually, the level, amount or concentration of TNF and/or IL-16 to a threshold level for each, wherein:
the threshold level for TNF is a value between at or about 7 pg/mL and at or about 25 pg/mL; and/or
the threshold level for IL-16 is a value between at or about 400 pg/mL and at or about 1000 pg/mL; and
(1) if the level, amount or concentration of TNF and/or IL-16 is at or above the respective threshold level, identifying the subject as at risk for developing a neurotoxicity following administration of the cell therapy; or
(2) if the level, amount or concentration of TNF and/or IL-16 is below the respective threshold level, identifying the subject as not at risk for developing a neurotoxicity following administration of the cell therapy.

### Claim 26 (depends on 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24)

The method of any of claims 2-24, wherein the agent or other treatment is or comprises an anti-IL-6 antibody, anti-IL-6R antibody or a steroid.

### Claim 27 (depends on 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24)

The method of any of claims 2-24, wherein the agent is or comprises tocilizumab, siltuximab or dexamethasone.

### Claim 28 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27)

The method of any of claims 1-27, wherein the neurotoxicity is severe neurotoxicity.

### Claim 29 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28)

The method of any of claims 1-28, wherein the neurotoxicity is grade 3 or higher neurotoxicity.

### Claim 30

A method of assessing likelihood of a response to a cell therapy, the method comprising:
assessing the level, amount or concentration of vascular endothelial growth factor C (VEGFC) and/or vascular endothelial growth factor receptor 1 (VEGFR1) in a biological sample, wherein the biological sample is from a subject having a chronic lymphoblastic leukemia (CLL) or a small lymphocytic lymphoma (SLL) that is a candidate for treatment with a cell therapy, said cell therapy comprising a dose of engineered cells comprising T cells expressing a chimeric antigen receptor (CAR) that binds cluster of differentiation 19 (CD19), wherein the biological sample is obtained from the subject prior to administering the cell therapy; and
comparing, individually, the level, amount or concentration of the VEGFC and/or VEGFR1 in the sample to a threshold level; wherein:
(1) if the level, amount or concentration of VEGFC and/or VEGFR1 is below the respective threshold level, identifying the subject as having a high likelihood of achieving a response to the cell therapy; or
(2) if the level, amount or concentration of VEGFC and/or VEGFR1 is at or above the respective threshold level, identifying the subject as having a low likelihood of achieving a response to the cell therapy.

### Claim 31

A method of selecting a subject for treatment with a cell therapy, wherein the method comprises:
assessing the level, amount or concentration of vascular endothelial growth factor C (VEGFC) and/or vascular endothelial growth factor receptor 1 (VEGFR1) in a biological sample, wherein the biological sample is from a subject having a chronic lymphoblastic leukemia (CLL) or a small lymphocytic lymphoma (SLL) that is a candidate for treatment with a cell therapy, said cell therapy comprising a dose of engineered cells comprising T cells expressing a chimeric antigen receptor (CAR) that binds cluster of differentiation 19 (CD19), wherein the biological sample is obtained from the subject prior to administering the cell therapy; and
selecting a subject who is likely to respond to treatment based on the results of determining a likelihood that a subject will achieve a response to the cell therapy by comparing, individually, the level, amount or concentration of the VEGFC and/or VEGFR1 in the sample to a threshold level for each; wherein:
(1) if the level, amount or concentration of VEGFC and/or VEGFR1 is below the respective threshold level, identifying the subject as having a high likelihood of achieving a response to the cell therapy; or
(2) if the level, amount or concentration of VEGFC and/or VEGFR1 is at or above the respective threshold level, identifying the subject as having a low likelihood of achieving a response to the cell therapy.

### Claim 32 (depends on 30, 31)

The method of claim 30 or claim 31, further comprising administering the cell therapy to the subject selected for treatment.

### Claim 33

A method for treatment, wherein the method comprises:
(a) selecting a subject who is likely to respond to treatment based on the results of determining a likelihood that a subject will achieve a response to the cell therapy by comparing, individually, the level, amount or concentration of vascular endothelial growth factor C (VEGFC) and/or vascular endothelial growth factor receptor 1 (VEGFR1) in a biological sample, to a threshold level for each, wherein:
(1) if the level, amount or concentration of VEGFC and/or VEGFR1 is below the respective threshold level, identifying the subject as having a high likelihood of achieving a response to the cell therapy; or
(2) if the level, amount or concentration of VEGFC and/or VEGFR1 is at or above the respective threshold level, identifying the subject as having a low likelihood of achieving a response to the cell therapy;
wherein the biological sample is from a subject having a CLL or a SLL that is a candidate for treatment with a cell therapy, said cell therapy comprising a dose of engineered cells comprising T cells expressing a chimeric antigen receptor (CAR) that binds cluster of differentiation 19 (CD19), wherein the biological sample is obtained from the subject prior to administering the cell therapy and/or the subject does not comprise the T cells expressing the CAR; and
(b) administering the cell therapy to a subject selected for treatment.

### Claim 34 (depends on 30, 31, 32, 33)

The method of any of claims 30-33, wherein:
the threshold level is within 25%, within 20%, within 15%, within 10% or within 5% and/or is within a standard deviation is at or about or above the median or mean level, amount or concentration of VEGFC and/or VEGFR1 in a biological sample obtained from a group of subjects prior to receiving a cell therapy, wherein each of the subjects of the group achieved a response, after administration of a dose of engineered cells expressing the CAR for treating the CLL or the SLL;
the threshold level is at or greater than 1.25-fold higher, at or greater than 1.3-fold higher, at or greater than 1.4-fold higher or at or greater than 1.5-fold higher than the median or mean level, amount or concentration of VEGFC and/or VEGFR1 in a biological sample obtained from a group of subjects prior to receiving a cell therapy, wherein each of the subjects of the group achieved a response, after administration of a dose of engineered cells expressing the CAR for treating the CLL or the SLL;
the threshold level is at or greater than 1.25-fold higher, at or greater than 1.3-fold higher, at or greater than 1.4-fold higher or at or greater than 1.5-fold higher than the level, amount or concentration of VEGFC and/or VEGFR1 in a biological sample obtained from a group of normal or healthy subjects that are not candidates for treatment with the cell therapy.

### Claim 35 (depends on 30, 31, 32, 33, 34)

The method of any of claims 30-34, the threshold level for VEGFC is a value between at or about 60 pg/mL and at or about 70 pg/mL.

### Claim 36 (depends on 30, 31, 32, 33, 34, 35)

The method of any of claims 30-35, the threshold level for VEGFR1 is a value between at or about 80 pg/mL and at or about 120 pg/mL.

### Claim 37 (depends on 30, 31, 32, 33, 34, 35, 36)

The method of any of claims 30-36, wherein:
the level, amount or concentration of both VEGFC and VEGFR1 are assessed;
the threshold level for VEGFC is a value between at or about 60 pg/mL and at or about 70 pg/mL; and
the threshold level for VEGFR1 is a value between at or about 80 pg/mL and at or about 120 pg/mL.

### Claim 38 (depends on 30, 31, 32, 33, 34, 35, 36, 37)

The method of any of claims 30-37, wherein the biological sample is or is obtained from a blood sample, a plasma sample, or a serum sample.

### Claim 39 (depends on 30, 31, 32, 33, 34, 35, 36, 37, 38)

The method of any of claims 30-38, wherein the assessing comprises:
(a) contacting a biological sample with one or more reagents capable of detecting, or that is specific for, VEGFC and/or VEGFR1, optionally wherein the one or more reagents comprise an antibody that specifically recognizes VEGFC and/or VEGFR1; and
(b) detecting the presence or absence of a complex comprising the one or more reagents and VEGFC and/or VEGFR1.

### Claim 40 (depends on 30, 31, 32, 33, 34, 35, 36, 37, 38, 39)

The method of any of claims 30-39, wherein the assessing comprises an immunoassay.

### Claim 41 (depends on 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40)

The method of any of claims 30-40, wherein the assessing comprises an enzyme-linked immunosorbent assay (ELISA), immunoblotting, immunoprecipitation, radioimmunoassay (RIA), immunostaining, a flow cytometry assay, surface plasmon resonance (SPR), a chemiluminescence assay, a lateral flow immunoassay, an inhibition assay or an avidity assay.

### Claim 42 (depends on 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41)

The method of any of claims 30-41, wherein the assessing comprises an enzyme-linked immunosorbent assay (ELISA), optionally a bead-based ELISA.

### Claim 43 (depends on 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42)

The method of any of claims 30-42, wherein the response comprises objective response.

### Claim 44 (depends on 43)

The method of claim 43, wherein the objective response comprises complete response (CR; also known in some cases as complete remission), complete remission with incomplete blood count recovery (CRi), complete remission (CR), CR with incomplete marrow recovery (CRi), nodular partial remission (nPR), partial response (PR).

### Claim 45 (depends on 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44)

The method of any of claims 30-44, wherein the response is response that is assessed at or about 1, 2, or 3 months or more after the initiation of administration of the cell therapy.

### Claim 46 (depends on 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45)

The method of any of claims 30-45, wherein the response is response that is assessed at or about 3 months after the initiation of administration of the cell therapy.

### Claim 47 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46)

The method of any of claims 1-46, further comprising, prior to the administration of the cell therapy, administering a lymphodepleting therapy to the subject.

### Claim 48 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47)

The method of any of claims 1-47, wherein the subject has been preconditioned with a lymphodepleting therapy.

### Claim 49 (depends on 48)

The method of claim 48, wherein the biological sample is obtained from the subject prior to administration of the lymphodepleting therapy to the subject.

### Claim 50 (depends on 48)

The method of claim 48, wherein the one or more parameters of disease burden is assessed prior to administration of the lymphodepleting therapy to the subject.

### Claim 51 (depends on 47, 48, 49, 50)

The method of any of claims 47-50, wherein the lymphodepleting therapy comprises the administration of fludarabine and/or cyclophosphamide.

### Claim 52 (depends on 47, 48, 49, 50, 51)

The method of any of claims 47-51, wherein the lymphodepleting therapy comprises administration of cyclophosphamide at about 200-400 mg/m2, optionally at or about 300 mg/m2, inclusive, and/or fludarabine at about 20-40 mg/m2, optionally 30 mg/m2, daily for 2-4 days, optionally for 3 days.

### Claim 53 (depends on 47, 48, 49, 50, 51, 52)

The method of any of claims 47-52, wherein the lymphodepleting therapy comprises administration of cyclophosphamide at or about 300 mg/m2 and fludarabine at about 30 mg/m2 daily for 3 days, optionally wherein the dose of cells is administered at least at or about 2-7 days after the lymphodepleting therapy or at least at or about 2-7 days after the initiation of the lymphodepleting therapy.

### Claim 54 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53)

The method of any of claims 1-53, further comprising administering a Bruton's Tyrosine Kinase inhibitor (BTKi) to the subject.

### Claim 55 (depends on 54)

The method of claim 54, wherein the BTKi is ibrutinib.

### Claim 56 (depends on 54, 55)

The method of claim 54 or claim 55, wherein the BTKi administration is initiated prior to the initiation of administration of the cell therapy.

### Claim 57 (depends on 56)

The method of claim 56, wherein the BTKi administration is continued until after the initiation of administration of the cell therapy.

### Claim 58 (depends on 56, 57)

The method of claim 56 or claim 57, wherein the BTKi administration is continued for at least about or about 90 days after the initiation of administration of the cell therapy.

### Claim 59 (depends on 55, 56, 57, 58)

The method of any of claims 55-58, wherein the ibrutinib is administered at a dose of at or about 140 mg to at or about 840 mg per day.

### Claim 60 (depends on 55, 56, 57, 58, 59)

The method of any of claims 55-59, wherein the ibrutinib is administered at a dose of at or about 280 mg to at or about 560 mg per day.

### Claim 61 (depends on 55, 56, 57, 58, 59, 60)

The method of any of claims 55-60, wherein the ibrutinib is administered at a dose of at or about 420 mg per day.

### Claim 62 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61)

The method of any of claims 1-61, wherein the disease or condition is a relapsed or refractory (r/r) CLL.

### Claim 63 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62)

The method of any of claims 1-62, wherein the disease or condition is a relapsed or refractory (r/r) SLL.

### Claim 64 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63)

The method of any of claims 1-63, wherein the dose of engineered cells comprises a defined ratio of CD4+ cells expressing the CAR to CD8+ cells expressing the CAR, optionally wherein the ratio is between approximately 1:3 and approximately 3:1.

### Claim 65 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64)

The method of any of claim 1-64, wherein the dose of engineered cells comprises a defined ratio of CD4+ cells expressing the CAR to CD8+ cells expressing the CAR that is or is approximately 1:1.

### Claim 66 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65)

The method of any of claims 1-65, wherein the dose of engineered cells comprises at or about 2.5×107 total CAR-expressing cells to at or about 1.0×108 total CAR-expressing cells.

### Claim 67 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66)

The method of any of claims 1-66, wherein the dose of engineered cells comprises at or about 2.5×107 total CAR-expressing cells.

### Claim 68 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66)

The method of any of claims 1-66, wherein the dose of engineered cells comprises at or about 5×107 total cells or total CAR-expressing cells.

### Claim 69 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66)

The method of any of claims 1-66, wherein the dose of engineered cells comprises at or about 1×108 total cells or total CAR-expressing cells.

### Claim 70 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69)

The method of any of claims 1-69, wherein administration of the cell therapy comprises administering a plurality of separate compositions, wherein the plurality of separate compositions comprises a first composition comprising one of the CD4+ T cells and the CD8+ T cells and a second composition comprising the other of the CD4+ T cells and the CD8+ T cells.

### Claim 71 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70)

The method of any of claims 1-70, wherein the first composition comprises the CD8+ T cells and the second composition comprises the CD4+ T cells.

### Claim 72 (depends on 71)

The method of claim 71, wherein the initiation of the administration of the first composition is carried out prior to the initiation of the administration of the second composition, optionally wherein the initiation of the administration of the first composition and the initiation of the administration of the second composition are carried out no more than 48 hours apart.

### Claim 73 (depends on 64, 65, 66, 67, 68, 69, 70, 71, 72)

The method of any of claim 64-72, wherein the CAR comprised by the CD4+ T cells and/or the CAR comprised by the CD8+ T cells comprises a CAR that is the same and/or wherein the CD4+ T cells and/or the CD8+ T cells are genetically engineered to express a CAR that is the same.

### Claim 74 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73)

The method of any of claims 1-73, wherein, prior to the administration of the cell therapy, the subject has been treated with one or more prior therapies for the CLL or SLL, other than another dose of cells expressing CAR or a lymphodepleting therapy, optionally at least two prior therapies.

### Claim 75 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74)

The method of any of claims 1-74, wherein, prior to the administration of the cell therapy, the subject has relapsed following remission after treatment with, or become refractory to, failed and/or was intolerant to treatment with two or more prior therapies.

### Claim 76 (depends on 74, 75)

The method of claim 74 or claim 75, wherein the one or more prior therapies are selected from a kinase inhibitor, optionally an inhibitor of Bruton's tyrosine kinase (BTK), optionally ibrutinib; venetoclax; a combination therapy comprising fludarabine and rituximab; radiation therapy; and hematopoietic stem cell transplantation (HSCT).

### Claim 77 (depends on 74, 75, 76)

The method of any of claims 74-76, wherein the one or more prior therapies comprise an inhibitor of Bruton's tyrosine kinase (BTK) and/or venetoclax.

### Claim 78 (depends on 74, 75, 76, 77)

The method of any of claims 74-77, wherein the one or more prior therapies comprise ibrutinib and venetoclax.

### Claim 79 (depends on 74, 75, 76, 77)

The method of any of claims 74-77, wherein the subject has relapsed following remission after treatment with, become refractory to failed treatment with and/or is intolerant to an inhibitor of Bruton's tyrosine kinase (BTK) and/or venetoclax.

### Claim 80 (depends on 74, 75, 76, 77, 78, 79)

The method of any of claims 74-79, wherein the subject has relapsed following remission after treatment with, become refractory to, failed treatment with and/or is intolerant to ibrutinib and venetoclax.

### Claim 81 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80)

The method of any of claims 1-80, wherein the engineered cells are primary T cells obtained from a subject.

### Claim 82 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81)

The method of any of claims 1-81, wherein the engineered cells are autologous to the subject.

### Claim 83 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82)

The method of any of claims 1-82, wherein:
the CAR comprises an extracellular antigen-binding domain specific for CD19, a transmembrane domain, a cytoplasmic signaling domain derived from a costimulatory molecule, which optionally is a 4-1BB, and a cytoplasmic signaling domain derived from a primary signaling ITAM-containing molecule, which optionally is a CD3zeta; and/or
the CAR comprises, in order, an extracellular antigen-binding domain specific for CD19, a transmembrane domain, a cytoplasmic signaling domain derived from a costimulatory molecule, and a cytoplasmic signaling domain derived from a primary signaling ITAM-containing molecule.

### Claim 84 (depends on 83)

The method of claim 83, wherein the antigen-binding domain is an scFv.

### Claim 85 (depends on 84)

The method of claim 84, wherein:
the scFv comprises a CDRL1 sequence of RASQDISKYLN (SEQ ID NO: 35), a CDRL2 sequence of SRLHSGV (SEQ ID NO: 36), and/or a CDRL3 sequence of GNTLPYTFG (SEQ ID NO: 37) and/or a CDRH1 sequence of DYGVS (SEQ ID NO: 38), a CDRH2 sequence of VIWGSETTYYNSALKS (SEQ ID NO: 39), and/or a CDRH3 sequence of YAMDYWG (SEQ ID NO: 40);
the scFv comprises a variable heavy chain region of FMC63 and a variable light chain region of FMC63 and/or a CDRL1 sequence of FMC63, a CDRL2 sequence of FMC63, a CDRL3 sequence of FMC63, a CDRH1 sequence of FMC63, a CDRH2 sequence of FMC63, and a CDRH3 sequence of FMC63 or binds to the same epitope as or competes for binding with any of the foregoing;
the scFv comprises a VH set forth in SEQ ID NO:41 and a VL set forth in SEQ ID NO: 42, optionally wherein the VH and VL are separated by a flexible linker, optionally wherein the flexible linker is or comprises the sequence set forth in SEQ ID NO:24; and/or
the scFv is or comprises the sequence set forth in SEQ ID NO:43.

### Claim 86 (depends on 83, 84, 85)

The method of any of claims 83-85, wherein the costimulatory signaling region is a signaling domain of CD28 or 4-1BB.

### Claim 87 (depends on 83, 84, 85, 86)

The method of any of claims 83-86, wherein the costimulatory signaling region is a signaling domain of 4-1BB.

### Claim 88 (depends on 83, 84, 85, 86, 87)

The method of any of claims 83-87, wherein the costimulatory domain comprises SEQ ID NO: 12 or a variant thereof having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity thereto.

### Claim 89 (depends on 83, 84, 85, 86, 87, 88)

The method of any of claims 83-88, wherein the primary signaling domain is a CD3zeta signaling domain.

### Claim 90 (depends on 83, 84, 85, 86, 87, 88, 89)

The method of any of claims 83-89, wherein the primary signaling domain comprises SEQ ID NO: 13, 14, or 15 having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity thereto.

### Claim 91 (depends on 83, 84, 85, 86, 87, 88, 89, 90)

The method of any of claims 83-90, wherein the CAR further comprises a spacer between the transmembrane domain and the antigen-binding domain.

### Claim 92 (depends on 91)

The method of claim 91, wherein the spacer is a polypeptide spacer that comprises or consists of all or a portion of an immunoglobulin hinge or a modified version thereof, optionally an IgG4 hinge, or a modified version thereof.

### Claim 93 (depends on 91, 92)

The method of claim 91 or claim 92, wherein the spacer is about 15 amino acids or less, and does not comprise a CD28 extracellular region or a CD8 extracellular region.

### Claim 94 (depends on 91, 92, 93)

The method of any of claims 91-93, wherein the spacer is at or about 12 amino acids in length.

### Claim 95 (depends on 91, 92, 93, 94)

The method of any of claims 91-94, wherein:
the spacer has or consists of the sequence of SEQ ID NO: 1, a sequence encoded by SEQ ID NO: 2, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34, or a variant of any of the foregoing having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity thereto; and/or
comprises or consists of the formula X1PPX2P, where X1 is glycine, cysteine or arginine and X2 is cysteine or threonine.

### Claim 96 (depends on 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95)

The method of any of claims 83-95, wherein:
the scFv comprises an amino acid sequence of RASQDISKYLN (SEQ ID NO: 35), an amino acid sequence of SRLHSGV (SEQ ID NO: 36), and/or an amino acid sequence of GNTLPYTFG (SEQ ID NO: 37) and/or an amino acid sequence of DYGVS (SEQ ID NO: 38), an amino acid sequence of VIWGSETTYYNSALKS (SEQ ID NO: 39), and/or an amino acid sequence of YAMDYWG (SEQ ID NO: 40) or wherein the scFv comprises a variable heavy chain region of FMC63 and a variable light chain region of FMC63 and/or a CDRL1 sequence of FMC63, a CDRL2 sequence of FMC63, a CDRL3 sequence of FMC63, a CDRH1 sequence of FMC63, a CDRH2 sequence of FMC63, and a CDRH3 sequence of FMC63 or binds to the same epitope as or competes for binding with any of the foregoing, and optionally wherein the scFv comprises, in order, a VH, a linker, optionally comprising SEQ ID NO: 24, and a VL, and/or the scFv comprises a flexible linker and/or comprises the amino acid sequence set forth as SEQ ID NO: 43;
the spacer is a polypeptide spacer that (a) comprises or consists of all or a portion of an immunoglobulin hinge or a modified version thereof or comprises about 15 amino acids or less, and does not comprise a CD28 extracellular region or a CD8 extracellular region, (b) comprises or consists of all or a portion of an immunoglobulin hinge, optionally an IgG4 hinge, or a modified version thereof and/or comprises about 15 amino acids or less, and does not comprise a CD28 extracellular region or a CD8 extracellular region, or (c) is at or about 12 amino acids in length and/or comprises or consists of all or a portion of an immunoglobulin hinge, optionally an IgG4, or a modified version thereof; or (d) has or consists of the sequence of SEQ ID NO: 1, a sequence encoded by SEQ ID NO: 2, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34, or a variant of any of the foregoing having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity thereto, or (e) comprises or consists of the formula X1PPX2P, where X1 is glycine, cysteine or arginine and X2 is cysteine or threonine;
the costimulatory domain comprises SEQ ID NO: 12 or a variant thereof having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity thereto; and/or
the primary signaling domain comprises SEQ ID NO: 13, 14 or 15 having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity thereto.

### Claim 97 (depends on 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96)

The method of any of claims 83-96, wherein:
the antigen binding domain comprises an scFv that comprises a variable heavy chain region of FMC63 and a variable light chain region of FMC63;
the CAR further comprises a spacer that is a polypeptide spacer comprising the sequence of SEQ ID NO: 1;
the costimulatory domain comprises SEQ ID NO: 12; and
the primary signaling domain comprises SEQ ID NO: 13, 14 or 15.

### Claim 98 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97)

The method of any of claims 1-97, wherein the subject is a human subject.

### Claim 99 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98)

An article of manufacture comprising a composition for a cell therapy, or one of a plurality of compositions for a cell therapy, comprising T cells expressing a CAR that binds CD19, and instructions for administering the cell therapy, wherein the instructions specify administering the T cell composition according to the methods of any of claims 1-98.

### Claim 100 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98)

A cell therapy comprising T cells expressing a CAR that binds CD19 for use in a method of treating a subject having a chronic lymphoblastic leukemia (CLL) or a small lymphocytic lymphoma (SLL), according to the methods of any of claims 1-98.